Back to Search
Start Over
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2879-2888. Date of Electronic Publication: 2022 Jul 23. - Publication Year :
- 2022
-
Abstract
- Considerable healthcare resource utilization and financial burden have been associated with the treatment of WM; however, the impact of health insurance status on outcomes has not been previously reported. We conducted a National Cancer Database analysis of newly diagnosed cases of active WM between 2004 and 2017 to evaluate the impact of insurance status on outcomes. For patients <65 years old ( n = 1249, male sex: 62.4%, median age: 58 years), significant insurance-based survival differences were observed on multivariable analysis; patients who were uninsured [ n = 63; HR 3.11 (95%CI, 1.77-5.45), p < 0.001], on Medicaid [ n = 87; HR 1.88 (95% CI, 1.01-3.48), p = 0.045], or on Medicare [ n = 122; HR 2.78 (95%CI, 1.76-4.38), p < 0.001], had inferior survival compared to patients with private insurance ( n = 977; reference). In patients ≥65 years, no insurance-based survival differences were found ( p = 0.10). Overall, significant insurance-based outcome disparities exist in WM. Further work is desperately needed to systematically uncover and address these disparities.
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 63
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 35876190
- Full Text :
- https://doi.org/10.1080/10428194.2022.2102623